Switch theme
Sign up to access all valuation multiples
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
2003
79
LTM Revenue $67.3M
LTM EBITDA -$59.7M
$1.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioLineRx has a last 12-month revenue (LTM) of $67.3M and a last 12-month EBITDA of -$59.7M.
In the most recent fiscal year, BioLineRx achieved revenue of $8.3M and an EBITDA of $1.1M.
BioLineRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioLineRx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $67.3M | XXX | $8.3M | XXX | XXX | XXX |
| Gross Profit | $46.9M | XXX | $5.6M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | -$59.7M | XXX | $1.1M | XXX | XXX | XXX |
| EBITDA Margin | -89% | XXX | 14% | XXX | XXX | XXX |
| EBIT | -$58.7M | XXX | -$5.5M | XXX | XXX | XXX |
| EBIT Margin | -87% | XXX | -66% | XXX | XXX | XXX |
| Net Profit | -$27.1M | XXX | -$2.6M | XXX | XXX | XXX |
| Net Margin | -40% | XXX | -32% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BioLineRx's stock price is ILS 0 (or $0).
BioLineRx has current market cap of ILS 49.1M (or $14.0M), and EV of ILS 4.5M (or $1.3M).
See BioLineRx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3M | $14.0M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BioLineRx has market cap of $14.0M and EV of $1.3M.
BioLineRx's trades at 0.2x EV/Revenue multiple, and 1.1x EV/EBITDA.
Equity research analysts estimate BioLineRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioLineRx has a P/E ratio of -1.8x.
See valuation multiples for BioLineRx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14.0M | XXX | $14.0M | XXX | XXX | XXX |
| EV (current) | $1.3M | XXX | $1.3M | XXX | XXX | XXX |
| EV/Revenue | 0.1x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | -0.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBIT | -0.1x | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | 0.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.8x | XXX | -5.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioLineRx's last 12 month revenue growth is -76%
BioLineRx's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
BioLineRx's rule of 40 is -1265% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioLineRx's rule of X is -278% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioLineRx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -76% | XXX | -6% | XXX | XXX | XXX |
| EBITDA Margin | -89% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | -39% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1265% | XXX | -62% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -278% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 134% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioLineRx acquired XXX companies to date.
Last acquisition by BioLineRx was XXXXXXXX, XXXXX XXXXX XXXXXX . BioLineRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioLineRx founded? | BioLineRx was founded in 2003. |
| Where is BioLineRx headquartered? | BioLineRx is headquartered in Israel. |
| How many employees does BioLineRx have? | As of today, BioLineRx has 79 employees. |
| Who is the CEO of BioLineRx? | BioLineRx's CEO is Mr. Philip A. Serlin, C.P.A.,M.B.A.. |
| Is BioLineRx publicy listed? | Yes, BioLineRx is a public company listed on TAE. |
| What is the stock symbol of BioLineRx? | BioLineRx trades under BLRX ticker. |
| When did BioLineRx go public? | BioLineRx went public in 2007. |
| Who are competitors of BioLineRx? | Similar companies to BioLineRx include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of BioLineRx? | BioLineRx's current market cap is $14.0M |
| What is the current revenue of BioLineRx? | BioLineRx's last 12 months revenue is $67.3M. |
| What is the current revenue growth of BioLineRx? | BioLineRx revenue growth (NTM/LTM) is -76%. |
| What is the current EV/Revenue multiple of BioLineRx? | Current revenue multiple of BioLineRx is 0.1x. |
| Is BioLineRx profitable? | Yes, BioLineRx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioLineRx? | BioLineRx's last 12 months EBITDA is -$59.7M. |
| What is BioLineRx's EBITDA margin? | BioLineRx's last 12 months EBITDA margin is -89%. |
| What is the current EV/EBITDA multiple of BioLineRx? | Current EBITDA multiple of BioLineRx is -0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
